The price of AbCellera Biologics Inc (NASDAQ: ABCL) closed at $4.49 in the last session, up 3.46% from day before closing price of $4.34. In other words, the price has increased by $+0.1500 from its previous closing price. On the day, 856243 shares were traded. ABCL stock price reached its highest trading level at $4.5350 during the session, while it also had its lowest trading level at $4.3500.
Ratios:
We take a closer look at ABCL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 26 ’23 when Thermopylae Holdings Ltd. bought 153,000 shares for $6.52 per share. The transaction valued at 997,728 led to the insider holds 56,012,493 shares of the business.
Booth Andrew bought 14,500 shares of ABCL for $99,325 on May 26 ’23. The Chief Financial Officer now owns 153,000 shares after completing the transaction at $6.85 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1.31B and an Enterprise Value of 631.39M. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.57 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 16.60 whereas that against EBITDA is -3.29.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $8.05, while it has fallen to a 52-week low of $3.87. The 50-Day Moving Average of the stock is 4.8836, while the 200-Day Moving Average is calculated to be 5.3015.
Shares Statistics:
According to the various share statistics, ABCL traded on average about 1.42M shares per day over the past 3-months and 1.02M shares per day over the past 10 days. A total of 290.82M shares are outstanding, with a floating share count of 205.17M. Insiders hold about 29.92% of the company’s shares, while institutions hold 38.39% stake in the company. Shares short for ABCL as of Mar 15, 2024 were 23.04M with a Short Ratio of 16.24, compared to 22.81M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.87% and a Short% of Float of 10.92%.
Earnings Estimates
The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.25, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.1 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.48 and -$1.01 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.69, with 6 analysts recommending between -$0.45 and -$0.99.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $11.02M. It ranges from a high estimate of $18.29M to a low estimate of $8.9M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $12.19M, an estimated decrease of -9.60% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $11.53M, an increase of 14.70% over than the figure of -$9.60% in the same quarter last year. There is a high estimate of $17.36M for the next quarter, whereas the lowest estimate is $9.22M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $77.46M, while the lowest revenue estimate was $36.9M, resulting in an average revenue estimate of $47.83M. In the same quarter a year ago, actual revenue was $38.02M, up 25.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $68.42M in the next fiscal year. The high estimate is $117.86M and the low estimate is $46.4M. The average revenue growth estimate for next year is up 43.00% from the average revenue estimate for this year.
